A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study will be a double-blind, randomized, multicenter trial to assess the safety and
efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of
azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12
hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of
Community Acquired Bacterial Pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Durata Therapeutics Inc., an affiliate of Allergan plc